Market Closed -
Toronto S.E.
03:59:59 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.7
CAD
|
+4.94%
|
|
+0.59%
|
-49.25%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
559.4
|
496.7
|
153.9
|
71.99
|
26.61
|
26.72
|
-
|
Enterprise Value (EV)
1 |
559.4
|
496.7
|
153.9
|
71.99
|
26.61
|
26.72
|
26.72
|
P/E ratio
|
-10.3
x
|
-6.65
x
|
-1.88
x
|
-1.27
x
|
-0.33
x
|
-0.24
x
|
-0.35
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
25.6
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
25.6
x
|
EV / EBITDA
|
-15.2
x
|
-7.12
x
|
-1.87
x
|
-1.24
x
|
-0.38
x
|
-0.32
x
|
-
|
EV / FCF
|
-18,745,938
x
|
-11,649,043
x
|
-2,806,630
x
|
-1,618,455
x
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-0%
|
-
|
-
|
-
|
Price to Book
|
-
|
3.33
x
|
1.71
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
5,074
|
5,924
|
5,932
|
6,153
|
7,942
|
15,718
|
-
|
Reference price
2 |
110.2
|
83.85
|
25.95
|
11.70
|
3.350
|
1.700
|
1.700
|
Announcement Date
|
3/10/20
|
3/23/21
|
3/22/22
|
3/23/23
|
3/26/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
1.042
|
EBITDA
1 |
-36.79
|
-69.81
|
-82.3
|
-58.03
|
-70.93
|
-83.74
|
-
|
EBIT
1 |
-37
|
-70
|
-82.49
|
-58.19
|
-71.05
|
-75.61
|
-54.31
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-5,210.53%
|
Earnings before Tax (EBT)
1 |
-36.2
|
-69.34
|
-82.37
|
-57.13
|
-69.49
|
-74.89
|
-54.32
|
Net income
1 |
-36.2
|
-69.34
|
-82.37
|
-57.13
|
-69.49
|
-74.89
|
-54.32
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-5,211.33%
|
EPS
2 |
-10.75
|
-12.62
|
-13.80
|
-9.220
|
-10.29
|
-6.972
|
-4.846
|
Free Cash Flow
|
-29.84
|
-42.64
|
-54.85
|
-44.48
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/20
|
3/23/21
|
3/22/22
|
3/23/23
|
3/26/24
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-14.25
|
-30.63
|
-14.89
|
-13.68
|
-13.65
|
-14.17
|
-18.79
|
-19.34
|
-16.05
|
-16.43
|
-18.19
|
-20.36
|
-21.44
|
-25.11
|
-
|
EBIT
1 |
-14.3
|
-30.69
|
-14.94
|
-13.72
|
-13.69
|
-14.21
|
-18.83
|
-19.37
|
-16.08
|
-16.46
|
-14.26
|
-12.56
|
-13.92
|
-14.94
|
-14.94
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-14.27
|
-30.66
|
-14.91
|
-13.58
|
-13.35
|
-13.66
|
-18.27
|
-18.93
|
-15.75
|
-16.22
|
-15.95
|
-16.29
|
-17.48
|
-19.92
|
-15.07
|
Net income
1 |
-14.27
|
-30.66
|
-14.91
|
-13.58
|
-13.35
|
-13.66
|
-18.27
|
-18.93
|
-15.75
|
-16.22
|
-15.95
|
-16.29
|
-17.48
|
-19.92
|
-15.07
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-2.455
|
-5.104
|
-2.338
|
-2.121
|
-2.253
|
-2.254
|
-3.005
|
-3.042
|
-2.422
|
-1.954
|
-1.113
|
-1.038
|
-1.100
|
-1.236
|
-0.9370
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/11/21
|
3/22/22
|
5/9/22
|
8/2/22
|
11/1/22
|
3/23/23
|
5/8/23
|
8/10/23
|
11/9/23
|
3/26/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-29.8
|
-42.6
|
-54.8
|
-44.5
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
25.20
|
15.20
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.14
|
0.1
|
0.27
|
0.03
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/20
|
3/23/21
|
3/22/22
|
3/23/23
|
3/26/24
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -49.25% | 19.52M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|